PT2882440T - Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa - Google Patents

Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa

Info

Publication number
PT2882440T
PT2882440T PT13748243T PT13748243T PT2882440T PT 2882440 T PT2882440 T PT 2882440T PT 13748243 T PT13748243 T PT 13748243T PT 13748243 T PT13748243 T PT 13748243T PT 2882440 T PT2882440 T PT 2882440T
Authority
PT
Portugal
Prior art keywords
inhibitor
pi3k
optionally
alpha
pharmaceutical combinations
Prior art date
Application number
PT13748243T
Other languages
English (en)
Inventor
Giordano C/O Novartis Institutes For Biomedical Research Inc Caponigro
Darrin C/O Novartis Vaccines And Diagnostics Inc Stuart
Parseval Laure C/O Novartis Pharma Ag Moutouh-De
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48980368&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2882440(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of PT2882440T publication Critical patent/PT2882440T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
PT13748243T 2012-08-07 2013-08-05 Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa PT2882440T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261680473P 2012-08-07 2012-08-07

Publications (1)

Publication Number Publication Date
PT2882440T true PT2882440T (pt) 2019-04-23

Family

ID=48980368

Family Applications (1)

Application Number Title Priority Date Filing Date
PT13748243T PT2882440T (pt) 2012-08-07 2013-08-05 Combinações farmacêuticas compreendendo um inibidor de braf, um inibidor de egfr e opcionalmente um inibidor de pi3k-alfa

Country Status (39)

Country Link
US (1) US9474754B2 (pt)
EP (2) EP2882440B1 (pt)
JP (3) JP6342396B2 (pt)
KR (1) KR102112885B1 (pt)
CN (1) CN104519887B (pt)
AR (1) AR092045A1 (pt)
AU (1) AU2013299841B8 (pt)
CA (1) CA2879548C (pt)
CL (1) CL2015000294A1 (pt)
CO (1) CO7200273A2 (pt)
CY (1) CY1122143T1 (pt)
DK (1) DK2882440T3 (pt)
EA (1) EA028420B1 (pt)
EC (1) ECSP15008695A (pt)
ES (1) ES2717911T3 (pt)
GT (1) GT201500025A (pt)
HK (2) HK1204976A1 (pt)
HR (1) HRP20190537T1 (pt)
HU (1) HUE042877T2 (pt)
IL (1) IL236934B (pt)
IN (1) IN2015DN00450A (pt)
JO (1) JOP20130236B1 (pt)
LT (1) LT2882440T (pt)
MA (1) MA37829A1 (pt)
MX (1) MX359403B (pt)
MY (1) MY176031A (pt)
NZ (1) NZ703940A (pt)
PE (2) PE20150673A1 (pt)
PH (1) PH12015500246A1 (pt)
PL (1) PL2882440T3 (pt)
PT (1) PT2882440T (pt)
RS (1) RS58734B1 (pt)
SG (1) SG11201500321YA (pt)
SI (1) SI2882440T1 (pt)
TN (1) TN2015000027A1 (pt)
TR (1) TR201904980T4 (pt)
TW (1) TWI607754B (pt)
UA (1) UA115786C2 (pt)
WO (1) WO2014025688A1 (pt)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR092045A1 (es) * 2012-08-07 2015-03-18 Novartis Ag Combinaciones farmaceuticas
HUE055072T2 (hu) 2013-03-21 2021-10-28 Array Biopharma Inc B-Raf gátlót és második gátlószert tartalmazó kombinációs terápia
WO2015145388A2 (en) * 2014-03-27 2015-10-01 Novartis Ag Methods of treating colorectal cancers harboring upstream wnt pathway mutations
EP3155126B1 (en) * 2014-06-16 2018-06-06 Worldwide Innovative Network Method for selecting personalized tri-therapy for cancer treatment
WO2016193955A1 (en) * 2015-06-04 2016-12-08 Giorgio Stassi Combinations of kinase inhibitors for treating colorectal cancer
EP3355886A1 (en) * 2015-08-28 2018-08-08 Novartis AG Pharmaceutical combination comprising the pi3k inhibitor alpelisib and the b-raf inhibitor dabrafenib; the use of such combination in the treatment or prevention of cancer
JP2018526375A (ja) * 2015-08-28 2018-09-13 ノバルティス アーゲー 組み合わせ療法
WO2017066664A1 (en) * 2015-10-16 2017-04-20 Millennium Pharmaceuticals, Inc. Combination therapy including a raf inhibitor for the treatment of colorectal cancer
HUE060653T2 (hu) * 2016-06-03 2023-04-28 Array Biopharma Inc Gyógyászati kombinációk
CN109715163B (zh) * 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
EP3661516A1 (en) * 2017-08-03 2020-06-10 Novartis AG Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor
AU2019353144B2 (en) 2018-10-05 2023-11-16 Annapurna Bio, Inc. Compounds and compositions for treating conditions associated with APJ receptor activity
TW202043225A (zh) * 2019-01-25 2020-12-01 英屬開曼群島商百濟神州有限公司 B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途
WO2020164997A1 (en) * 2019-02-12 2020-08-20 Bayer Aktiengesellschaft Combination of pi3k-inhibitors
WO2023145530A1 (ja) * 2022-01-27 2023-08-03 国立大学法人東北大学 癌治療剤
WO2023230554A1 (en) 2022-05-25 2023-11-30 Pfizer Inc. Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer
WO2024073364A1 (en) * 2022-09-26 2024-04-04 Beigene, Ltd. Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
MY150697A (en) 2007-04-10 2014-02-28 Exelixis Inc Methods of treating cancer using pyridopyrimdinone inhibitors of p13k alpha
UA104147C2 (uk) * 2008-09-10 2014-01-10 Новартис Аг Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань
CA2771369A1 (en) * 2009-08-24 2011-03-10 Genentech, Inc. Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels
JO3002B1 (ar) * 2009-08-28 2016-09-05 Irm Llc مركبات و تركيبات كمثبطات كيناز بروتين
KR20120097496A (ko) * 2009-10-12 2012-09-04 글락소스미스클라인 엘엘씨 조합물
US20120045433A1 (en) 2010-08-17 2012-02-23 Kapil Dhingra Combination therapy
EP2637661B1 (en) * 2010-11-08 2017-12-20 Novartis AG Use of (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)- pyridin-4-yl]-thiazol-2-yl}-amide) in the treatment of EGFR dependent diseases or diseases that have acquired resistance to agents that target EGFR family members
WO2013070998A1 (en) 2011-11-10 2013-05-16 Memorial Sloan-Kettering Cancer Center TREATMENT OF OVARIAN CANCER WITH 2-AMINO-4H-NAPHTHO[1,2-b]PYRAN-3-CARBONITRILES
JP6150813B2 (ja) * 2011-11-11 2017-06-21 ノバルティス アーゲー 増殖性疾患の治療方法
AR092045A1 (es) * 2012-08-07 2015-03-18 Novartis Ag Combinaciones farmaceuticas

Also Published As

Publication number Publication date
BR112015002384A8 (pt) 2019-07-30
LT2882440T (lt) 2019-04-25
CN104519887A (zh) 2015-04-15
BR112015002384A2 (pt) 2017-07-04
JP6974669B2 (ja) 2021-12-01
AU2013299841B2 (en) 2016-11-24
RS58734B1 (sr) 2019-06-28
SG11201500321YA (en) 2015-04-29
TW201410247A (zh) 2014-03-16
CA2879548A1 (en) 2014-02-13
EP3574904A1 (en) 2019-12-04
CN104519887B (zh) 2017-06-27
JP6595024B2 (ja) 2019-10-23
JP2018109022A (ja) 2018-07-12
JP2020019780A (ja) 2020-02-06
HK1211831A1 (en) 2016-06-03
PL2882440T3 (pl) 2019-07-31
TWI607754B (zh) 2017-12-11
MX359403B (es) 2018-09-26
TR201904980T4 (tr) 2019-05-21
PH12015500246B1 (en) 2015-03-30
KR20150040905A (ko) 2015-04-15
EA201590332A1 (ru) 2015-06-30
CL2015000294A1 (es) 2015-05-08
HUE042877T2 (hu) 2019-07-29
DK2882440T3 (da) 2019-05-06
EA028420B1 (ru) 2017-11-30
MX2015001732A (es) 2015-06-03
HRP20190537T1 (hr) 2019-06-28
MA37829A1 (fr) 2017-01-31
KR102112885B1 (ko) 2020-05-19
CY1122143T1 (el) 2020-11-25
US9474754B2 (en) 2016-10-25
JP6342396B2 (ja) 2018-06-13
EP2882440B1 (en) 2019-02-27
ECSP15008695A (es) 2019-03-29
JOP20130236B1 (ar) 2021-08-17
IN2015DN00450A (pt) 2015-06-26
HK1204976A1 (en) 2015-12-11
TN2015000027A1 (en) 2016-06-29
CA2879548C (en) 2020-07-21
AU2013299841B8 (en) 2017-01-05
WO2014025688A1 (en) 2014-02-13
EP2882440A1 (en) 2015-06-17
AU2013299841A8 (en) 2017-01-05
CO7200273A2 (es) 2015-02-27
PE20150673A1 (es) 2015-05-20
PE20191655A1 (es) 2019-11-07
MY176031A (en) 2020-07-22
GT201500025A (es) 2017-09-28
PH12015500246A1 (en) 2015-03-30
ES2717911T3 (es) 2019-06-26
NZ703940A (en) 2018-04-27
AR092045A1 (es) 2015-03-18
SI2882440T1 (sl) 2019-05-31
JP2015524472A (ja) 2015-08-24
UA115786C2 (uk) 2017-12-26
IL236934B (en) 2018-11-29
US20150265616A1 (en) 2015-09-24
AU2013299841A1 (en) 2015-02-12

Similar Documents

Publication Publication Date Title
HK1204976A1 (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor b-raf egfr pi3k-alpha
HK1202545A1 (en) New diazaspirocycloalkane and azaspirocycloalkane
HK1206795A1 (en) Rapid aneuploidy detection
GB201218801D0 (en) Device,method and software
EP2821748A4 (en) DEVICE FOR FINDING A BEACH AND METHOD FOR FINDING A BEACH
PL2831055T3 (pl) Zdolne do polimeryzacji alkilideno-1,3-dioksolan-2-ony i ich zastosowanie
GB201906245D0 (en) A method and device
EP2893664A4 (en) METHOD AND ARRANGEMENTS FOR A TEST SEQUENCE
HK1183362A1 (zh) 查詢方法和裝置
HK1200396A1 (zh) 攪拌裝置以及具備其的吐出裝置和吐出方法
EP2903772A4 (en) MATERIALS, METHODS AND DEVICES FOR CONNECTING LINES
ZA201206179B (en) Software fingerprinting
HK1210930A1 (en) A device and a method for anastomosis
TWI562080B (en) Systes and methods for operation activation
EP2837627A4 (en) AMIDOPYRIDINE DERIVATIVE AND USE THEREOF
EP2808387A4 (en) OLIGONUCLEOTIDE FOR HIV IDENTIFICATION, HIV IDENTIFICATION KIT AND HIV PROOF PROCEDURE
EP2836857A4 (en) COUPLER, PROCESS AND APPLICATIONS
AU2013200291A1 (en) Methods and devices for context set selection
EP2821964A4 (en) COLOR SCALE DETERMINING DEVICE, COLOR SCANNING DETERMINING METHOD, AND COLOR SCANNING DETERMINING PROGRAM
EP2869486A4 (en) RECEIVING DEVICE, METHOD, AND PROGRAM
AU2012902452A0 (en) A Review and Challenge System
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201204745D0 (en) Identifying proximity and location